Desloratadine

ApprovedCompleted

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Urticaria

Conditions

Urticaria

Trial Timeline

Jul 1, 2003 → Mar 1, 2005

NCT ID

NCT00795522

About Desloratadine

Desloratadine is a approved stage product being developed by Organon for Urticaria. The current trial status is completed. This product is registered under clinical trial identifier NCT00795522. Target conditions include Urticaria.

What happened to similar drugs?

1 of 20 similar drugs in Urticaria were approved

Approved (1) Terminated (2) Active (17)

🔄CT-P39 + EU-approved XolairCelltrionPhase 3

🔄LOU064NovartisPhase 3

🔄Ligelizumab + OmalizumabNovartisPhase 3

🔄LOU064 (blinded) + placeboNovartisPhase 3

🔄Remibrutinib + Remibrutinib matching placebo + Dupilumab + Placebo solution for injectionNovartisPhase 3

🔄omalizumab + omalizumabNovartisPhase 3

🔄RemibrutinibNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00723736	Pre-clinical	Completed	Dec 1, 2007	Jun 1, 2008	Rhinitis
NCT00724698	Pre-clinical	Completed	Oct 1, 2005	Dec 1, 2007	Rhinitis
NCT00311844	Approved	Completed	Mar 1, 2005	May 28, 2005	Conjunctivitis, Allergic
NCT00795522	Approved	Completed	Jul 1, 2003	Mar 1, 2005	Urticaria
NCT00805324	Phase 3	Completed	May 1, 2003	Aug 1, 2003	Rhinitis, Allergic, Seasonal
NCT00805584	Approved	Completed	May 1, 2003	Jun 1, 2003	Rhinitis, Allergic, Seasonal
NCT00817076	Phase 3	Completed	Mar 1, 2003	Jul 1, 2003	Dermatitis, Atopic
NCT00795158	Phase 3	Completed	Nov 1, 2002	Jan 1, 2004	Urticaria

Competing Products

20 competing products in Urticaria

See all competitors

Product	Company	Stage	Hype Score
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
CT-P39 + EU-approved Xolair	Celltrion	Phase 3	40
Omalizumab	Celltrion	Pre-clinical	33
LY3454738 + Placebo	Eli Lilly	Phase 2	27
AZD1981 + Placebo	AstraZeneca	Phase 2	35
Benralizumab + Placebo and Benralizumab	AstraZeneca	Phase 2	27
LOU064	Novartis	Phase 3	40
Ligelizumab + Omalizumab	Novartis	Phase 3	40
Ligelizumab + Placebo	Novartis	Phase 1	21
Omalizumab	Novartis	Phase 2	35
canakinumab	Novartis	Phase 2	35
LOU064	Novartis	Phase 2	35
Omalizumab (Xolair) + Placebo	Novartis	Phase 2/3	38
LOU064 Arm 1 + LOU064 Arm 2 + LOU064 Arm 3 + LOU064 Arm 4 + LOU064 Arm 5 + LOU064 Arm 6 + Placebo arm	Novartis	Phase 2	35
LOU064 (blinded) + placebo	Novartis	Phase 3	47
Remibrutinib + Remibrutinib matching placebo + Dupilumab + Placebo solution for injection	Novartis	Phase 3	47